Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr outlined the company’s strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell engager (TCE) antibodies for solid tumors. Lehr described TCEs as antibodies that “bridge the gap” between immune T-cells and cancer cells by binding both CD3 on T-cells and tumor antigens on cancer cells, effectively forcing an immune-cancer cell interaction.
Focus on externally discovered T-cell engagers
Lehr said Context operates as a “search and development” company with no in-house research, relying on externally discovered programs and focusing capital on clinical advancement. The company currently has three TCE programs, all directed at solid tumors:
- CT-76 (Claudin 6) – clinical-stage; initial focus includes ovarian, endometrial, and testicular cancers, with increasing emphasis on ovarian cancer.
- CT-95 (mesothelin) – clinical-stage; initial focus includes pancreatic, ovarian, and mesothelioma, with increasing emphasis on pancreatic cancer.
- CT-202 (Nectin-4) – expected to enter the clinic soon; Nectin-4 is broadly expressed across multiple tumor types including triple-negative breast cancer, bladder cancer, non-small cell lung cancer, and colorectal cancer, among others.
Upcoming data cadence and near-term milestones
Mesothelin Phase 1 data is expected about a quarter later, with Lehr stating the company has guided to mid-2026 for that update. He added that CT-202 (Nectin-4) is expected to enter the clinic in Q2, which he said could create a cadence of “almost quarterly updates” from Q2 onward as the programs mature.
Technology approach: high-affinity CD3 with focus on therapeutic window
Lehr emphasized Context’s belief in using high-affinity CD3 to drive potency, acknowledging that cytokine release syndrome (CRS) has historically been a primary dose-limiting toxicity for TCEs. However, he argued that clinical techniques such as step dosing and steroid prophylaxis have reduced CRS as the primary constraint, shifting attention toward on-target/off-tumor liabilities that define a program’s therapeutic window. He cited areas of monitoring by target:
- Claudin 6: liver monitoring
- Mesothelin: lung monitoring
- Nectin-4: skin monitoring
Strategically, Lehr said Context is initially developing its TCEs as monotherapies to address resistance to standard-of-care therapies, while seeing longer-term potential for combinations. He argued TCE toxicities tend to cluster in the first two doses and then diminish, which can make them attractive combination partners compared to modalities with cumulative toxicities, such as antibody-drug conjugates (ADCs).
Program highlights: Claudin 6, mesothelin, and Nectin-4
Claudin 6 (CT-76). Lehr described Claudin 6 as a target “only expressed in cancer cells,” and said Context is particularly interested in ovarian cancer, including use after ADCs and potentially in earlier lines over time. He noted that, in Context’s experience, nearly 80% of platinum-resistant ovarian cancer patients are Claudin 6 positive, and he described observed expression levels as typically high (H-scores in the 200–250 range).
He also highlighted a key development consideration: Claudin 6 is in a protein family similar to Claudin 3 and Claudin 4, which are found in the liver, making selectivity important. Context’s preclinical work, he said, showed roughly 500-fold selectivity versus Claudin 3 and 4 in an in vitro cell death assay. In the ongoing trial, Lehr said the company was in cohort five as of its last update and is “wrapping up” the Phase 1A dose escalation ahead of the Q2 disclosure.
Lehr provided an update from an earlier snapshot of data he said was shared around “Halloween,” when 12 patients had been enrolled. At that time, Context had safety through cohort four and efficacy through cohort three. He said pharmacokinetics were dose-proportional and linear with no evidence of anti-drug antibodies, and he said exposure supported potential dosing every two to three weeks, despite weekly dosing in the trial. On efficacy, he said cohort three was at the edge of the active range and included one ovarian patient with a “deep and durable confirmed response,” described as approximately a 50% tumor reduction that deepened to 85%. Lehr added the patient was ADC-experienced, having previously received mirvetuximab.
Mesothelin (CT-95). Lehr called mesothelin a larger market opportunity due to broad tumor expression. For Phase 1A, he said Context is concentrating on pancreatic, ovarian, and mesothelioma, noting these patients are nearly universally mesothelin-positive and may not require screening. He also detailed challenges with the target: mesothelin is cleaved (creating shed antigen) and is found in the lungs, necessitating binding to the membrane-attached portion and avoiding lung binding.
To address safety concerns that have affected other mesothelin programs, Lehr said Context engineered CT-95 with ~40-fold lower affinity for mesothelin than competitors, drawing a comparison to strategies used by CAR-T developers Arcellx and Autolus to reduce tonic stimulation and improve safety. He said Context was in cohort four and was seeing “really exciting safety” so far, adding that some TCE peers have struggled to reach active doses due to toxicity. Lehr also discussed how shed mesothelin can reduce potency and referenced a preclinical comparison where a historical comparator showed a marked potency loss in the presence of shed antigen.
Nectin-4 (CT-202). Lehr described CT-202 as the company’s largest opportunity by patient population, highlighting that Nectin-4 is present across many solid tumors. He referenced the approved Nectin-4 ADC PADCEV in metastatic bladder cancer and noted skin toxicity as a prominent issue, stating that about a third of patients in the real world discontinue PADCEV due to skin-related side effects.
To mitigate dermal toxicity risk, Lehr said Context made both its Nectin-4 binder and its CD3 binder pH-dependent, aiming to preferentially bind in the acidic tumor microenvironment rather than normal tissue such as skin. He characterized the impact as reducing skin binding by roughly 25% and further reducing CD3-mediated T-cell activation for any antibody that still binds skin. Lehr said Context believes it is the only company to have successfully completed GLP toxicology with a CD3 binder against Nectin-4, and described the preclinical tox profile as “exceptional.” He also discussed preclinical benchmarking showing comparable in vivo efficacy in mouse tumor models, while reporting reduced IL-6 induction at high doses compared to a parental antibody.
Financing and runway
Lehr said Context raised $115 million in 2025 and described the company as “well-financed,” with cash expected to fund operations through its material inflection points this year and beyond. He reiterated key upcoming milestones: Claudin 6 data in Q2, mesothelin data in mid-2026, and Nectin-4 entering the clinic in Q2, alongside additional updates thereafter.
About Context Therapeutics (NASDAQ:CNTX)
Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.
With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.
Further Reading
- Five stocks we like better than Context Therapeutics
- Central banks just did something they haven’t done since 1967
- Silver Is the New Oil—And the World’s Running Dry
- SpaceX IPO Confirmed: Claim Your Stake Today
- What central banks are doing with gold right now
- “I just bought 10,000 shares of a $5 stock…”
